biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 6/2025 | 03-04-2025 | Decyzja Zarządu dotycząca procesu certyfikacji FDA dla systemu BACTEROMIC

Previous Post

Related Posts

01.04.2025

Scope Fluidics Named “Stock Exchange Company of the Year 2024″ by Puls Biznesu

0
08.01.2025

Scope Fluidics Reports Positive Results from Software Development for Rapid Detection

0
08.01.2025

EAP Results Confirm Readiness for BACTEROMIC System Market Deployment

0